Please try another search
For the six months ended 30 June 2018, FIT Biotech Oy revenues was not reported. Net loss increased 33% to EUR1.8M. Higher net loss reflects Other operating expenses increase of 39% to EUR916K (expense), Other Operating Income decrease of 72% to EUR97K (income), Depreciation/Amortization increase of 26% to EUR102K (expense).
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | -0.24 | -0.08 | ||
Operating Income | -1.77 | -1.52 | -1.32 | -1.56 |
Net Income | -1.83 | -1.92 | -1.38 | -2.18 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 1.14 | 1.07 | 1.24 | 1.43 |
Total Liabilities | 14.26 | 14.39 | 13.85 | 13.83 |
Total Equity | -13.12 | -13.32 | -12.61 | -12.4 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -1.85 | -2.5 | -1.4 | -2.49 |
Cash From Investing Activities | -0.05 | -0.05 | -0.07 | -0.16 |
Cash From Financing Activities | 1.5 | 2.5 | 1 | 1.29 |
Net Change in Cash | -0.39 | -0.06 | -0.47 | -1.36 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review